Barclays
TVTX icon

Barclays’s Travere Therapeutics TVTX Stock Holding History

Barclays’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.39M Sell
248,861
-120,669
-33% -$3.61M ﹤0.01% 1605
2025
Q4 		$14.1M Buy
369,530
+20,528
+6% +$667K ﹤0.01% 1447
2025
Q3 		$8.34M Sell
349,002
-179,524
-34% -$3.38M ﹤0.01% 1805
2025
Q2 		$7.82M Sell
528,526
-293,306
-36% -$4.86M ﹤0.01% 1750
2025
Q1 		$14.7M Buy
821,832
+425,262
+107% +$8.63M ﹤0.01% 1178
2024
Q4 		$6.91M Buy
396,570
+227,802
+135% +$4.03M ﹤0.01% 1874
2024
Q3 		$2.36M Sell
168,768
-17,544
-9% -$183K ﹤0.01% 2721
2024
Q2 		$1.53M Buy
186,312
+8,555
+5% +$57.6K ﹤0.01% 2327
2024
Q1 		$1.37M Sell
177,757
-209,052
-54% -$1.76M ﹤0.01% 2876
2023
Q4 		$3.48M Buy
386,809
+98,155
+34% +$715K ﹤0.01% 2425
2023
Q3 		$2.58M Buy
288,654
+36,071
+14% +$509K ﹤0.01% 1728
2023
Q2 		$3.88M Buy
252,583
+49,797
+25% +$906K ﹤0.01% 1490
2023
Q1 		$4.56M Buy
202,786
+18,000
+10% +$383K ﹤0.01% 1609
2022
Q4 		$3.89M Buy
184,786
+47,873
+35% +$1.01M ﹤0.01% 1800
2022
Q3 		$3.37M Buy
136,913
+111,357
+436% +$2.88M ﹤0.01% 1399
2022
Q2 		$619K Sell
25,556
-23,345
-48% -$587K ﹤0.01% 2708
2022
Q1 		$1.26M Buy
+48,901
New +$1.3M ﹤0.01% 2217
2020
Q4 		– Sell
-24,386
Closed -$450K – 5156
2020
Q3 		$450K Sell
24,386
-14,606
-37% -$284K ﹤0.01% 3307
2020
Q2 		$796K Buy
38,992
+2,200
+6% +$35K ﹤0.01% 2954
2020
Q1 		$537K Sell
36,792
-38,305
-51% -$576K ﹤0.01% 3527
2019
Q4 		$1.07M Buy
75,097
+45,744
+156% +$584K ﹤0.01% 3620
2019
Q3 		$341K Sell
29,353
-15,598
-35% -$258K ﹤0.01% 4561
2019
Q2 		$903K Buy
44,951
+25,175
+127% +$497K ﹤0.01% 3782
2019
Q1 		$447K Buy
19,776
+16,351
+477% +$361K ﹤0.01% 4219
2018
Q4 		$77K Sell
3,425
-28,195
-89% -$701K ﹤0.01% 5224
2018
Q3 		$908K Buy
31,620
+23,585
+294% +$674K ﹤0.01% 3716
2018
Q2 		$220K Sell
8,035
-12,154
-60% -$324K ﹤0.01% 4635
2018
Q1 		$450K Buy
20,189
+8,152
+68% +$194K ﹤0.01% 4079
2017
Q4 		$254K Sell
12,037
-15,078
-56% -$345K ﹤0.01% 4480
2017
Q3 		$675K Buy
27,115
+24,943
+1,148% +$549K ﹤0.01% 3341
2017
Q2 		$42K Sell
2,172
-7,620
-78% -$138K ﹤0.01% 5454
2017
Q1 		$180K Sell
9,792
-8,649
-47% -$169K ﹤0.01% 4425
2016
Q4 		$349K Buy
18,441
+14,509
+369% +$297K ﹤0.01% 3694
2016
Q3 		$87K Buy
3,932
+3,833
+3,872% +$73K ﹤0.01% 4606
2016
Q2 		$2K Buy
+99
New +$1.6K ﹤0.01% 5991
2016
Q1 		– Sell
-310,933
Closed -$5.91M – 6440
2015
Q4 		$5.91M Buy
310,933
+306,903
+7,615% +$6.13M 0.01% 1209
2015
Q3 		$81K Sell
4,030
-248
-6% -$7.35K ﹤0.01% 4746
2015
Q2 		$141K Buy
4,278
+3,306
+340% +$90.5K ﹤0.01% 4409
2015
Q1 		$22K Sell
972
-296
-23% -$4.51K ﹤0.01% 5779
2014
Q4 		$16K Buy
1,268
+569
+81% +$5.89K ﹤0.01% 6448
2014
Q3 		$6K Buy
699
+78
+13% +$918 ﹤0.01% 7124
2014
Q2 		$7K Buy
621
+102
+20% +$1.38K ﹤0.01% 7005
2014
Q1 		$11K Buy
+519
New +$7.98K ﹤0.01% 6892

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Barclays's TVTX Position: Q1 2026 in Review

Barclays reduced its Travere Therapeutics (TVTX) stake by 33% in Q1 2026, selling an estimated $3.61M and leaving 248,861 shares worth $7.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1605.

Barclays first reported a position in TVTX in Q1 2014 and has held it in 43 quarters since. The position peaked at $14.7M in Q1 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Barclays held 248,861 shares of Travere Therapeutics worth $7.39M as of Q1 2026.
  • Barclays sold 120,669 Travere Therapeutics shares in Q1 2026, an estimated $3.61M.
  • Travere Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1605 holding.
  • Barclays first reported a position in Travere Therapeutics in Q1 2014 and has held it in 43 quarters since.
  • Barclays's Travere Therapeutics position peaked at $14.7M in Q1 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.